Literature DB >> 16730261

Mechanisms of immune evasion by tumors.

Charles G Drake1, Elizabeth Jaffee, Drew M Pardoll.   

Abstract

In the past decade, basic studies in animal models have begun to elucidate the physiological barriers which impede a successful antitumor immune response. These barriers operate at a number of levels, and involve the tumor, the tumor microenvironment and various components of the innate and adaptive immune systems. In this review, we discuss the multiple mechanisms by which tumors evade an immune response, with an emphasis on clinically relevant strategies to overcome these inhibitory checkpoints.

Entities:  

Mesh:

Year:  2006        PMID: 16730261     DOI: 10.1016/S0065-2776(06)90002-9

Source DB:  PubMed          Journal:  Adv Immunol        ISSN: 0065-2776            Impact factor:   3.543


  265 in total

1.  Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts.

Authors:  Sid P Kerkar; Pawel Muranski; Andrew Kaiser; Andrea Boni; Luis Sanchez-Perez; Zhiya Yu; Douglas C Palmer; Robert N Reger; Zachary A Borman; Ling Zhang; Richard A Morgan; Luca Gattinoni; Steven A Rosenberg; Giorgio Trinchieri; Nicholas P Restifo
Journal:  Cancer Res       Date:  2010-07-20       Impact factor: 12.701

2.  Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity.

Authors:  Valsamo Anagnostou; Mark Yarchoan; Aaron R Hansen; Hao Wang; Franco Verde; Elad Sharon; Deborah Collyar; Laura Q M Chow; Patrick M Forde
Journal:  Clin Cancer Res       Date:  2017-09-01       Impact factor: 12.531

Review 3.  Harnessing cancer immunotherapy during the unexploited immediate perioperative period.

Authors:  Pini Matzner; Elad Sandbank; Elad Neeman; Oded Zmora; Vijaya Gottumukkala; Shamgar Ben-Eliyahu
Journal:  Nat Rev Clin Oncol       Date:  2020-02-17       Impact factor: 66.675

Review 4.  Prospects and challenges of building a cancer vaccine targeting telomerase.

Authors:  Robert H Vonderheide
Journal:  Biochimie       Date:  2007-07-17       Impact factor: 4.079

Review 5.  Immunotherapy and immunoescape in colorectal cancer.

Authors:  Guillermo Mazzolini; Oihana Murillo; Catalina Atorrasagasti; Juan Dubrot; Iñigo Tirapu; Miguel Rizzo; Ainhoa Arina; Carlos Alfaro; Arantza Azpilicueta; Carmen Berasain; José L Perez-Gracia; Alvaro Gonzalez; Ignacio Melero
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

6.  Mannan-modified adenovirus encoding VEGFR-2 as a vaccine to induce anti-tumor immunity.

Authors:  Jie Zhang; Ying Wang; Yang Wu; Zhen-Yu Ding; Xin-Mei Luo; Wu-Ning Zhong; Jie Liu; Xiang-Yu Xia; Guo-Hua Deng; Yao-Tiao Deng; Yu-Quan Wei; Yu Jiang
Journal:  J Cancer Res Clin Oncol       Date:  2014-02-14       Impact factor: 4.553

7.  Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale.

Authors:  Xiuli Wang; Araceli Naranjo; Christine E Brown; Cherrilyn Bautista; Chinglam W Wong; Wen-Chung Chang; Brenda Aguilar; Julie R Ostberg; Stanley R Riddell; Stephen J Forman; Michael C Jensen
Journal:  J Immunother       Date:  2012 Nov-Dec       Impact factor: 4.456

Review 8.  Targeting PVR (CD155) and its receptors in anti-tumor therapy.

Authors:  Paola Kučan Brlić; Tihana Lenac Roviš; Guy Cinamon; Pini Tsukerman; Ofer Mandelboim; Stipan Jonjić
Journal:  Cell Mol Immunol       Date:  2018-10-01       Impact factor: 11.530

9.  Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity.

Authors:  Ingunn M Stromnes; J Scott Brockenbrough; Kamel Izeradjene; Markus A Carlson; Carlos Cuevas; Randi M Simmons; Philip D Greenberg; Sunil R Hingorani
Journal:  Gut       Date:  2014-02-20       Impact factor: 23.059

10.  Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism.

Authors:  Lyse A Norian; Paulo C Rodriguez; Leigh A O'Mara; Jovanny Zabaleta; Augusto C Ochoa; Marina Cella; Paul M Allen
Journal:  Cancer Res       Date:  2009-03-17       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.